The Challenge: A Faster, More Complex Launch Environment
In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch. Many of us have experienced a disappointing launch when everything we anticipated pointed to success. Today, launches are more complex than they were a decade ago. Teams are operating under tighter timelines while managing reimbursement readiness, market adoption, competitive shifts, and the need to align medical, commercial, and field strategy all at the right moment.1
Another very important part of launch readiness is identifying which expert voices will matter most to shape perception and adoption. Teams that stand out are those who engage the right experts early, translate data into meaningful education, and build credibility.2
Why KOL Strategy is Key
Pharma activity in 2026 continues to highlight just how quickly the landscape is evolving.3, 4 With approvals, clinical readouts, and regulatory decisions unfolding across therapeutic areas, teams need to communicate complex science with speed and clarity.
The role of clinical experts is more important than ever. Research shows that respected peer voices can influence professional practice and support the adoption of evidence-based care.5 During launch, that perspective helps translate clinical data into real-world context that supports the most informed decision-making. When building your bureau, ask yourself: what area of strength is each expert providing? Obviously, they’re all experts in the same therapeutic area, but some are better with patients than others. Some are better at diagnosing and some with clinical data. Perhaps some better understand the managed care landscape, while others are able to influence treatment guidelines.6
At the same time, how those experts are engaged matters. Clear, consistent, and relevant communication helps build trust and long-term credibility with all the key stakeholders.7 At the end of the day, it’s about making sure your speakers are telling the right story.
Time to Turn Strategy into Action
Even with strong data and a clear timeline, teams face a familiar challenge: alignment on which expert voices will have the greatest impact and how to make science resonate with busy clinicians for the long-term. A well-structured KOL strategy starts with identifying the key experts, understanding where clinical questions remain, and shaping the peer-to-peer education around real-world patient care—not just messaging.2
Vision2Voice works with pharmaceutical, biotech, and medical device teams to support KOL identification and mapping, advisory boards, speaker programs, strategic planning, curriculum development, and clinical council support. The goal is simple: create structure and clarity so teams can engage the right experts and deliver education that is incredibly useful to healthcare professionals (HCPs).
Launch Reality: Where Strategy Execution Breaks Down
Identifying and engaging the right key opinion leaders (KOLs) and key external experts (KEEs) early plays an important role in shaping launch readiness—but, what tends to happen is that the process often becomes appreciably more difficult than it should be.
The most common pain points we hear from clients include:
- Competing for the same KOLs
- Inaccurate KOL rankings due to outdated or incomplete data
- Missing emerging voices, lack of awareness for rising stars
- Fragmented outreach across internal teams, leading to duplication and mixed messaging
- Difficulty comparing expert engagement data, limiting the ability to determine the true measurable impact of each expert being considered
For many organizations, the KOL/KEE identification process is still manual and fragmented. Launch teams are relying on cumbersome spreadsheets, legacy databases, and internal lists that take too long to validate or are outdated. By the time delayed insights are compiled and ready to act on, the opportunity to enlist the most desired experts may already have passed. And…let’s face it, even when key experts are finally identified using lists and spreadsheets, it is not always easy to compare the key data side-by-side to determine the best experts to include in your peer-to-peer programs.
The Solution: A Connected Approach to KOL Engagement
Vision2Voiceʼs KNECT™ system was designed with this in mind. By integrating insights from our KOL/KEE mapping studies, KNECT helps teams better understand and utilize clinical activity, academic output, and other data to identify, evaluate, and engage expert voices more efficiently and strategically.
With a more connected view of the KOL landscape, your teams can easily:
- Search more comprehensively
- Compare experts more effectively
- Map networks more clearly
- Build the right cadre of speakers that will most effectively deliver your message
If your team is preparing for launch or reevaluating your KOL strategy, this is an opportunity to take a more structured approach to building your most talented speaker bureau with the help of Vision2Voice’s KOL Identification and the KNECTTM portal
To learn more, schedule time with our team so we can discuss how a more strategic model for KOL identification, engagement, and training can help your team move faster, communicate more effectively, and launch with greater confidence!
Works Cited
- Medical Affairs Professional Society. 2025 Medical Affairs Launch Readiness and Execution Benchmark Report. 2 Dec. 2025, https://medicalaffairs.org/benchmark-report-2025-medical-affairs-launch-readiness-and-execution-benchmark-report/.
- Medical Affairs Professional Society. External Scientific Engagement (Field Medical) Standards and Guidance Document. 2024, https://medicalaffairs.org/standards-guidance-external-scientific-engagement/.
- U.S. Food and Drug Administration. “Novel Drug Approvals for 2026.” FDA, 27 May 2026, http s://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026.
- Hargreaves, Ben. “5 Clinical Readouts to Watch in H1 2026.” BioSpace, 5 Jan. 2026, https://ww w.biospace.com/drug-development/5-clinical-readouts-to-watch-in-h1-2026.
- Flodgren, Gerd, et al. “Local Opinion Leaders: Effects on Professional Practice and Healthcare Outcomes.” Cochrane Database of Systematic Reviews, no. 6, 2019, Art. No. CD000125. PubMed, https://pubmed.ncbi.nlm.nih.gov/31232458/.
- OʼBrien, Mary Ann, et al. “Educational Outreach Visits: Effects on Professional Practice and Health Care Outcomes.” Cochrane Database of Systematic Reviews, no. 4, 2007, Art. No. CD000409. PubMed, https://pubmed.ncbi.nlm.nih.gov/17943742/.
- Farley, Margaret. “Reputation Stewardship: Driving Stakeholder Action and Business Momentum.” Pharmaceutical Executive, https://www.pharmexec.com/view/reputation-stewardship-driving-stakeholder-action-business-momentum.
